Orum Taking Novel ADC Approach To Protein Degradation
New Funding To Advance Lead Candidates
Orum Therapeutics executives talk to Scrip on the next steps for the targeted protein degradation pioneer after a large-scale financing and on likely developments in the space in the coming years.
You may also be interested in...
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
EuBiologics CEO Yeong Ok Baik sat down with Scrip at CPhI Korea to talk about why he wants to develop vaccines for global public health needs and what plans are in store for its late-stage recombinant protein candidate for COVID-19.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.